Cardiff Oncology Earning Date (CRDF)

USA |NASDAQ |USD

CRDF Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 2, 2022 Sep 2022 - - $-0.17
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 2, 2022 Sep 2022 - - $86.00K

Cardiff Oncology's next earnings date is Wednesday, Nov 2, 2022 for the fiscal quarter ending Sep 2022.

CRDF Earnings Date & History Chart

CRDF Earnings & Revenue Forecast

CRDF Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $-0.92 $-1.15 $-0.68

CRDF Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-0.92 $-0.92 $-1.01

CRDF Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $150.00K $0.00 $400.00K

CRDF Earnings Date & Revenue History

CRDF Earnings History

|
Show More
Show More

CRDF Revenue History

|
Show More
Show More

Cardiff Oncology Next Earnings Date & Report

CRDF Next Earnings Date & Report Preview: Sep 2022 (FQ)

CRDF's next earnings date is Wednesday, Nov 2, 2022 for the fiscal quarter ending Sep 30, 2022.

Cardiff Oncology Previous Earnings Dates & Reports

CRDF Previous Earnings Date & Report Recap: Jun 2022 (FQ)

Cardiff Oncology's previous earnings date was Aug 3, 2022 for its fiscal quarter ended Jun 30, 2022.

CRDF Previous Earnings Date & Report Recap: Dec 2021 (FY)

Cardiff Oncology's previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.

CRDF's earnings per share (EPS) was $-0.71, missing the consensus analysts forecast of $-0.66 by 7.58% , and higher than the previous year's EPS (Dec 2020) by -40.34%.

Revenues were $359.00K, better than the forecast of $200.00K by 79.50%, and down by -1.91% from previous year's revenue.

The company reported a net income of $-28.29M.

Cardiff Oncology reported a free cash flow of $-23.25M for its fiscal year, compared to $-16.53M a year ago.

The company ended the fiscal year with $3.12M in total debt, an increase of 258.71% compared to the previous year.